KYM-001

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameKYM-001
Drug Alias NameKYM-001
ClassificationSmall molecules > Proteolysis-Targeting Chimera (PROTAC)
Mechanisms of ActionInterleukin-1 receptor-associated kinase 4 inhibitorsProteolysis
TargetsInterleukin-1 receptor-associated kinase 4
Therapy Area/IndicationsLymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesKymera Therapeutics IncSanofi
China Registration ClassN/A

Develop Information

Active CompaniesSanofiKymera Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsLymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A